Efffect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients  

作　　者：杨金奎 狄福松 何戎华 朱学素 王德全 杨明功 王颜钢 袁申元 陈家伟 

机构地区：[1]Department of Endocrinology, Tongren Hospital, Capital University of Medical Sciences, Beijing 100730, China [2]The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China [3]The First Affiliated Hospital, Shandong Medical University, Ji'nan 250012, China [4]The First Affiliated Hospital, Anhui Medical University, Hefei 230022, China

出　　处：《Chinese Medical Journal》2003年第5期785-787,共3页中华医学杂志（英文版）

摘　　要：Objective We designed a multi-center, double-blind, randomized, parallel, with metformin controlled clinical trial to evaluate the efficacy and safety of low dose rosiglitazone combined with sulphonylurea therapy in type 2 diabetic patients who were inadequately controlled with sulphonylurea alone.Methods Patients were treated with 4 mg rosiglitazone once daily plus sulphonylurea (test group) or 0.5 g metformin twice daily plus sulphonylurea (control group) for 12 weeks. The mean levels of HbA 1c, fasting and postprandial plasma glucose were recorded and compared between the two groups.Results The mean levels of HbA 1c decreased by 1.09% and 0.95% in the test group (n=102) and control group (n=96) respectively. Fasting and postprandial plasma glucose levels in the test group decreased by 25.0% and 35.6%, and in the control group, decreased by 17.7% and 23.8% as compared with the baseline (both P<0.01). No liver damage was found.Conclusion Combination treatment of rosiglitazone and sulphonylurea can effectively improve glycemic control in type 2 diabetic patients inadequately controlled with sulphonylurea alone.Objective We designed a multi-center, double-blind, randomized, parallel, with metformin controlled clinical trial to evaluate the efficacy and safety of low dose rosiglitazone combined with sulphonylurea therapy in type 2 diabetic patients who were inadequately controlled with sulphonylurea alone.Methods Patients were treated with 4 mg rosiglitazone once daily plus sulphonylurea (test group) or 0.5 g metformin twice daily plus sulphonylurea (control group) for 12 weeks. The mean levels of HbA 1c, fasting and postprandial plasma glucose were recorded and compared between the two groups.Results The mean levels of HbA 1c decreased by 1.09% and 0.95% in the test group (n=102) and control group (n=96) respectively. Fasting and postprandial plasma glucose levels in the test group decreased by 25.0% and 35.6%, and in the control group, decreased by 17.7% and 23.8% as compared with the baseline (both P<0.01). No liver damage was found.Conclusion Combination treatment of rosiglitazone and sulphonylurea can effectively improve glycemic control in type 2 diabetic patients inadequately controlled with sulphonylurea alone.

关 键 词：type 2 diabetes ROSIGLITAZONE SULFONYLUREA 

分 类 号：R587.1[医药卫生—内分泌]